In The News
BioCentury Explores Early-Stage Investing in “Formative Years”
Avalon’s Need for Speed
In a quest to unlock VCs’ process of biotech company formation, BioCentury interviewed Jay Lichter, Ph.D. and asked about his approach to sourcing ideas and incubating and funding early-stage companies.
Avalon looks for a mix of build-to-buy deals and uncommitted companies. The firm generally prefers asset-centric investing, where a company is built around a focused therapeutic opportunity versus broad platforms or big biology.
The article further explores the process behind the collaboration with GSK and how they can get from first conversation to a funded company in about four months – a speedy process compared to the industry norm.